Equities Analysts Offer Predictions for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Investment analysts at Leerink Partnrs lowered their FY2029 earnings per share estimates for shares of Caribou Biosciences in a research report issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of $0.26 for the year, down from their previous estimate of $0.28. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Several other research analysts have also recently issued reports on CRBU. Bank of America decreased their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Caribou Biosciences presently has an average rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $0.74 on Thursday. The business has a fifty day moving average of $1.03 and a 200-day moving average of $1.57. The stock has a market cap of $68.36 million, a price-to-earnings ratio of -0.45 and a beta of 2.36. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $4.21.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Centric Wealth Management bought a new position in Caribou Biosciences during the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. lifted its position in shares of Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after purchasing an additional 21,416 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after acquiring an additional 9,148 shares during the period. Diametric Capital LP bought a new stake in Caribou Biosciences in the 4th quarter valued at $42,000. Finally, US Bancorp DE grew its position in Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares in the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.